A team of researchers at Monash University, Swiss Tropical & Public Health Institute and the University of Nebraska have prepared aryl hydantoin compounds for the treatment of schistosomiasis.

Fused pyrimidine compounds acting as menin (MEN1)/MLL interaction inhibitors have been described in a Biomea Fusion Inc. patent and reported to be useful for the treatment of cancer, osteoporosis, autoimmune and inflammatory diseases, among others.

Ankh Life Sciences Ltd. have identified polycyclic compounds reported to be useful for the treatment of bacterial, fungal and viral infection.

Eli Lilly & Co. has patented new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of Aicardi-Goutieres syndrome, dermatomyositis, systemic lupus erythematosus and lupus nephritis.

Aeovian Pharmaceuticals Inc. has disclosed new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of neurodegenerative diseases.

Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of inflammation and autoimmune disease.

Researchers at Cerevance Inc. and Cerevance Ltd. have identified heterobicyclic amides acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of aging, diabetic nephropathy, glaucoma, inflammatory disorders, metabolic syndrome, obesity and rheumatoid arthritis, among others.

Haisco Pharmaceutical Group Co. Ltd. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

LG Chem Ltd. has disclosed diacylglycerol kinase α (DGK-α, DGKA) inhibitors reported to be useful for the treatment of cancer.

Nanjing Shijiang Medicine Technology Co. Ltd. has described phosphorus compounds reported to be useful for the treatment of cancer.